EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Everjoy Health Group Co Ltd (002162) fair value: what the stock is really worth

We calculate from audited financials what Everjoy Health Group Co Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Industrials · CN · ISIN CNE1000006M2

EH Thin data Sep 13, 2026

Everjoy Health Group Co Ltd

002162 · SHE

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value ¥2.21 · Strongly overvalued (−46%)
!Quality 53/100
!Weak Growth (revenue 5y −2.3 %/yr)
!Thin margins · 1.1% net margin (TTM)
Low debt · generates free cash flow
!Trails peers (1/14)
!Narrow moat 26/100
!Evidence only low, so the estimate is less certain
!Weak on past: 6 out of 100
!Weak on dividend: 12 out of 100
Watch Everjoy Health Group Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥8.49 ¥2.61 Fair Value ¥2.21 Mar 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range ¥2.61 – ¥8.49 · fair‑value band ¥1.41 – ¥2.75 · the ¥4.13 price screens above the ¥2.21 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Everjoy Health Group Co.,Ltd. engages in the production and sale of building materials in China. It offers vitrified stone, marble, marble slabs, glazed tiles, rock slabs, and artistic porcelain, supplemented by exterior wall cladding, decorative tiles, border tiles, corner tiles, and other accessories.

Show more

Everjoy Health Group Co.,Ltd. engages in the production and sale of building materials in China. It offers vitrified stone, marble, marble slabs, glazed tiles, rock slabs, and artistic porcelain, supplemented by exterior wall cladding, decorative tiles, border tiles, corner tiles, and other accessories. The company is also involved in the health care and medical care services; investment management; hotel operations; and offers training and education services. Health Group Co.,Ltd. was founded in 1993 and is headquartered in Shanghai, China.

Stock analysis

Everjoy Health Group Co Ltd (002162) currently trades at ¥4.13, while our model-based Fair Value estimate is ¥2.21, implying the stock looks roughly 86.9% overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of ¥0.6000 per share, and 0 of the 24 models we run sit above the ¥4.13 price.

Bear case: the Dividend Discount group reads lowest at ¥0.2400, and 24 of the 24 models stay below the price. Evidence for this calculation is low.

Scenario range: ¥1.41 (bear) to ¥2.75 (bull), the price of ¥4.13 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Industrials sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Everjoy Health Group Co Ltd reported revenue of 1.1B CNY in FY2025 versus 1.3B CNY in FY2021, a compound −4.2%/yr. Reported net income was 6.7M CNY in FY2025, compounding −38.2%/yr from FY2021.

Key figures

Market cap 3.8B CNY (≈ $566M) · P/E ratio 413.0 · P/S ratio 2.62 · EPS (TTM) ¥0.0100 · Dividend yield 0.6% · Net margin 0.6% · Return on equity 1.4% · Return on assets (EBIT) −2.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 36% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Industrials peers we cover trades at −35% fair-value upside, at −46%, 002162 screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (¥0.0700 to ¥1.09). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ¥1.41 Fair Value ¥2.21 Bull ¥2.75
Model Each model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (¥0.0070 per share) are deliberately not added. Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence Evidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF ¥0.2500 ¥0.3600 ¥0.5700 79
Growth DCF ¥0.2600 ¥0.3700 ¥0.5500 78
Residual Income ¥0.6000 ¥0.5600 ¥0.4000 76
All 24 models by family
DCF Models
FCF DCF ¥0.2500 ¥0.3600 ¥0.5700 79
Owner Earnings ¥0.1200 ¥0.1800 ¥0.3100 74
5Y Revenue Exit ¥0.2000 ¥0.3200 ¥0.5000 71
5Y EBITDA Exit ¥0.5100 ¥0.8400 ¥1.29 74
5Y P/E Exit ¥0.1000 ¥0.1500 ¥0.2100 71
10Y Revenue Exit ¥0.2100 ¥0.3200 ¥0.4400 67
10Y EBITDA Exit ¥0.4000 ¥0.6500 ¥0.9500 68
10Y P/E Exit ¥0.1600 ¥0.2100 ¥0.2500 65
Earnings-Based
Graham-Dodd ¥0.0500 ¥0.0900 ¥0.1000 67
EPV ¥0.0500 ¥0.0700 ¥0.0900 73
Dividend Discount
Gordon GGM ¥0.1900 ¥0.2400 ¥0.2800 69
DDM Multi-Stage ¥0.1900 ¥0.2500 ¥0.3200 67
Multiples
P/E Multiple ¥0.1200 ¥0.1500 ¥0.1900 63
P/S Multiple ¥0.0900 ¥0.1200 ¥0.1600 58
P/B Multiple ¥0.0900 ¥0.1200 ¥0.1600 55
EV/EBIT ¥0.3100 ¥0.4400 ¥0.5700 65
EV/EBITDA ¥0.7900 ¥1.09 ¥1.38 67
EV/Revenue ¥0.1900 ¥0.3200 ¥0.4400 52
Asset-Based
NCAV (Graham) ¥0.4500 ¥0.6000 ¥0.8900 54
Growth DCF
Growth DCF ¥0.2600 ¥0.3700 ¥0.5500 78
Rev-Margin DCF ¥0.2000 ¥0.3300 ¥0.4900 72
Economic Profit
Residual Income ¥0.6000 ¥0.5600 ¥0.4000 76
ROIC Compounder ¥0.0500 ¥0.0700 ¥0.0900 72
Growth Earnings
Growth-Adj P/E ¥0.0800 ¥0.1200 ¥0.1500 68

Open the full fair value analysis →

Notify me when 002162 reaches fair value

Put 002162 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 53/100

Of which business quality 51 · Market factors (momentum, volatility) 38

Profitability 22
Margins and returns on capital today
Quality Growth 43
Are margins and returns improving?
Cashflow 44
Earnings quality: real cash, not paper profit
Fin. Strength 47
Balance sheet, leverage, solvency risk
Investment 96
Disciplined investing over empire-building
Low Volatility 68
Calm price path (market factor)
Momentum 28
Price trend over the last 3–12 months (market factor)
52W Momentum 20
Distance to the 52-week high (market factor)
Net Issuance 84
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality Growth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−11.8%
Revenue growth 3 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.0%
Revenue growth 5 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.3%
Revenue growth 21 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.9%
What shareholders gained per year (last 5 years) What the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−31.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−32.4%
Dividend (yield on the price)0.6%
Pace: 5 vs 10 years Two data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−32% vs −8%, slowing
Profit margin 2020 to 2025 Operating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 3%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes This turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+48.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.

002162 screens 87% overvalued. Compare with Trane Technologies plc →

Compare Everjoy Health Group Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Building Products & Equipment · 250 stocks

Beats the industry median on 1/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 53 · Below median
Profitability
Return on equity (TTM) 1% · Below median
Return on assets 1% · Below median
Net margin (TTM) 1% · Below median
Operating margin (TTM) 2% · Below median
Growth and dividend
Revenue growth 8% · Above median
Dividend yield (TTM) 0.6% · Bottom 25%
Balance sheet
Debt / equity 0.34× · Above median

Valuation Multiplesvs Building Products & Equipment median · lower = cheaper

P/E (TTM) 413.0× · Priciest 25%
P/B 4.10× · Priciest 25%
P/S (TTM) 3.14× · Priciest 25%
P/FCF 15.6× · Priciest 25%
EV/EBITDA 61.5× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 5
FUTURE (revenue growth)38 · sector 11
PAST (return on equity)6 · sector 22
HEALTH (low debt)83 · sector 95
DIVIDEND (yield)12 · sector 40

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Building Products & Equipment stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Trane Technologies plc TT $442.52 $208.50 −53%
Johnson Controls International plc JCI $146.01 $38.59 −74%
Carrier Global Corporation CARR $57.46 $16.85 −71%
Compagnie de Saint-Gobain S.A SGO €71.52 €93.50 +31%
Geberit AG GEBN CHF 546.40 CHF 297.73 −46%
Lennox International Inc LII $366.04 $294.98 −19%
Madison Air Solutions Corporation MAIR $25.21 $15.34 −39%
Kingspan Group KRX €102.50 €66.79 −35%
Masco Corporation MAS $68.52 $53.22 −22%
Carlisle Companies Incorporated CSL $335.24 $340.70 +2%

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Everjoy Health Group Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/002162

Frequently asked questions

Is Everjoy Health Group Co Ltd (002162) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of ¥2.21 versus a price of ¥4.13, about −46% upside (overvalued).
What is the fair value of 002162?
Our model-based fair value for Everjoy Health Group Co Ltd is ¥2.21 (as of Sep 13, 2026), built from audited fundamentals. The current price: ¥4.13.
What is the quality score of 002162?
Everjoy Health Group Co Ltd has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Everjoy Health Group Co Ltd (002162)?
Our model-based price target is the fair value of ¥2.21 (as of Sep 13, 2026) from 24 valuation models. Cautious scenario ¥1.41, optimistic scenario ¥2.75. It is a calculation from audited fundamentals, not an analyst target.
What is the Everjoy Health Group Co Ltd stock forecast for 2026?
Our models put fair value at ¥2.21, about −46% upside versus a price of ¥4.13 (overvalued). Cautious scenario ¥1.41, optimistic scenario ¥2.75. The calculation is refreshed regularly with new filings.
What is the revenue of Everjoy Health Group Co Ltd (002162)?
Everjoy Health Group Co Ltd reported trailing-twelve-month revenue of about 1.1B CNY (latest available figure, as of Sep 13, 2026).
Does Everjoy Health Group Co Ltd pay a dividend?
Everjoy Health Group Co Ltd currently shows a dividend yield of about 0.59% relative to its recent price (as of Sep 13, 2026).
What growth is priced into Everjoy Health Group Co Ltd (002162)?
For today's price to be fair in a discounted-cash-flow model, Everjoy Health Group Co Ltd would have to grow free cash flow by +48.7 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -2.3 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of 002162 use?
Our models discount Everjoy Health Group Co Ltd at 10.5 %: a base by market capitalisation (small), damped by beta 0.53, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Everjoy Health Group Co Ltd that is +48.7 % per year a year over ten years, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Everjoy Health Group Co Ltd (002162) delivered so far?
Over the past 5 years revenue at Everjoy Health Group Co Ltd grew -2.3 % a year. The price currently implies +48.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Everjoy Health Group Co Ltd (002162) growing?
The median revenue growth in the sector is +4.6 % a year. That is the yardstick for the growth priced into Everjoy Health Group Co Ltd (+48.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Everjoy Health Group Co Ltd (002162)?
The free-cash-flow yield on the price is 0.85 %: that much free cash flow Everjoy Health Group Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Everjoy Health Group Co Ltd (002162)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Everjoy Health Group Co Ltd it is ¥2.21 per share (as of Sep 13, 2026), against a price of ¥4.13. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Everjoy Health Group Co Ltd stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 002162 trades above its calculated fair value: price ¥4.13, fair value ¥2.21, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002162?
No. The price is what the market pays today (¥4.13); the fair value is what the company's own numbers justify (¥2.21). For Everjoy Health Group Co Ltd the two are ¥1.92 per share apart. That gap is exactly why we show both numbers side by side.
How much is Everjoy Health Group Co Ltd worth?
The market values Everjoy Health Group Co Ltd at about 3.8B CNY (market capitalisation, as of Sep 13, 2026). Per share that is ¥4.13; our models calculate a fair value of ¥2.21 per share.
What do the bullish and bearish scenarios say about 002162?
Our models span a range for Everjoy Health Group Co Ltd: cautious scenario ¥1.41, base ¥2.21, optimistic ¥2.75 per share (as of Sep 13, 2026, price ¥4.13). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 002162?
Everjoy Health Group Co Ltd trades at a price-to-earnings ratio of 413.0 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥2.21 is built from several models across several years. Other multiples: P/B 4.1, P/S 3.1, EV/EBITDA 61.5.
How solid is the balance sheet of Everjoy Health Group Co Ltd (002162)?
Balance-sheet figures for Everjoy Health Group Co Ltd (as of Sep 13, 2026): return on equity 1.4%, debt of 0.34 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 002162 from its 52-week high?
Everjoy Health Group Co Ltd trades at ¥4.13, about 36% below its 52-week high of ¥6.45 and 15% above the low of ¥3.58 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of ¥2.21 is for.
Which stocks are comparable to Everjoy Health Group Co Ltd?
From the same area (Industrials) we also value Trane Technologies plc, Johnson Controls International plc, Carrier Global Corporation, Compagnie de Saint-Gobain S.A, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Everjoy Health Group Co Ltd stock attractive at the current price?
The data as of Sep 13, 2026: price ¥4.13, calculated fair value ¥2.21 (−46%), Quality Score 53/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002162 calculated?
We run Everjoy Health Group Co Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥2.21, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Everjoy Health Group Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Everjoy Health Group Co Ltd right now?
The price sits above even our optimistic bull case (¥2.75). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥1.41 to ¥2.75) leaves room in how you read the outcome.

Key figures of Everjoy Health Group Co Ltd

How large is the market capitalisation of Everjoy Health Group Co Ltd (002162)?
The market capitalisation of Everjoy Health Group Co Ltd is 3.8B CNY (≈ $566M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Everjoy Health Group Co Ltd (002162)?
The price-to-sales ratio of Everjoy Health Group Co Ltd is 2.62 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Everjoy Health Group Co Ltd (002162)?
Earnings per share at Everjoy Health Group Co Ltd are ¥0.0100 (price ÷ EPS = P/E 413.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Everjoy Health Group Co Ltd (002162)?
The dividend yield of Everjoy Health Group Co Ltd is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Everjoy Health Group Co Ltd (002162)?
The net margin of Everjoy Health Group Co Ltd is 0.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Everjoy Health Group Co Ltd (002162)?
The return on equity (ROE) of Everjoy Health Group Co Ltd is 1.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Everjoy Health Group Co Ltd (002162)?
On an EBIT basis the return on assets of Everjoy Health Group Co Ltd is −2.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Everjoy Health Group Co Ltd (002162)?
The operating margin of Everjoy Health Group Co Ltd is 2.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Everjoy Health Group Co Ltd (002162)?
Revenue at Everjoy Health Group Co Ltd is growing +7.6% versus a year earlier (3y avg −3.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Everjoy Health Group Co Ltd (002162)?
Earnings per share at Everjoy Health Group Co Ltd are growing −34.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Everjoy Health Group Co Ltd (002162) carry?
The net debt of Everjoy Health Group Co Ltd is 277M CNY (fiscal year 2025, ≈ 8.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Everjoy Health Group Co Ltd in the live analysis

One click puts Everjoy Health Group Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.